Recent Updates
Recently added Catalysts
ADMA Negative Sentiment Score: 20/100

ADMA INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of ADMA Biologics, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm

Key Takeaway: A shareholder class action lawsuit has been initiated against ADMA Biologics, Inc. The complaint contends that the company made false representations regarding its business, operations, and financial prospects. Specific allegations include undisclosed related party transactions and the use of channel stuffing to modify revenue recognition. Additionally, the lawsuit highlights deficiencies in the company's internal controls. Investors who purchased shares during a specific period and incurred losses are encouraged to reach out to Holzer & Holzer, LLC for legal assistance.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against ADMA, alleging false and misleading statements.
  • The lawsuit claims that ADMA engaged in undisclosed related party transactions.
  • It is alleged that ADMA used channel stuffing to inflate revenue figures.
  • The company is said to lack adequate internal controls.

Full Press Release Details

ATLANTA, June 11, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against ADMA Biologics, Inc. (“ADMA”) (NASDAQ: ADMA). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts regarding ADMA’s business, operations, and prospects, including allegations that: (1) ADMA engaged in an undisclosed related party transaction; (2) ADMA used channel stuffing to create an appearance of revenue; and (3) ADMA lacked adequate internal controls.
If you purchased ADMA shares between August 9, 2024 and March 25, 2026, and experienced a loss on that investment, you are encouraged to discuss your legal rights by contacting Marshall P. Dees, Esq. at mdees@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/adma-biologics/ for more information.
The deadline to ask the court to be appointed lead plaintiff in the case is August 10, 2026.
Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.
Marshall P. Dees, Esq.
(888) 508-6832 (toll-free)

Tags

Frequently Asked Questions

What is the lawsuit against ADMA Biologics about?

The lawsuit claims ADMA misled investors and failed to disclose key facts about its operations.

Who can participate in the lawsuit?

Investors who purchased ADMA shares between August 9, 2024, and March 25, 2026, may participate.

When is the deadline to become lead plaintiff?

The deadline to request lead plaintiff status is August 10, 2026.

Who is representing the shareholders in this case?

Holzer & Holzer, LLC is representing shareholders in the class action lawsuit.

How can investors contact for more information?

Investors can contact Marshall P. Dees, Esq. at mdees@holzerlaw.com or call (888) 508-6832.

Last updated: Jun 11, 2026